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 Genetic factors have an important role in the incidence of osteopenia in thalassemia patients. The
purpose of this study was to investigate the effect of the Pro12Ala polymorphism of the peroxisome
proliferator-activated receptor-γ (PPARγ) gene on bone mineral density (BMD) and subsequently,
the rate of osteopenia in β-thalassemia major (β-TM) patients. Blood samples were obtained from 156
β-TM patients referred to the Tehran and Qazvin Thalassemia Clinics. Samples were analyzed for
polymorphisms of the PPARγ gene using polymerase chain reaction-restriction fragment length poly-
morphism (RFLP)-based methods. Multivariate analysis was used to investigate the relationship
between the risk of osteopenia and the PPARγ gene polymorphism. Correlation analysis showed that
there was a significant association between homozygous wild-type genotypes with susceptibility to
osteopenia in β-TM patients (p ¼ 0.024). Logistic regression analysis showed that the risk of
osteopenia was significantly (p <0.05) higher in the homozygous wild-type genotype than carriers of
the rare alleles. Furthermore, the associations were strengthened in men with a homozygous wild-type
genotype after adjustment for age and body mass index (BMI) (p <0.05). This study suggests that the
Pro12Ala polymorphism of the PPARγ gene might be an independent factor in BMD level and
osteopenia in thalassemia patients.
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INTRODUCTION
β-Thalassemia (β-thal) disease is a type of hemoglobinopathy that is
caused by a disorder in partial or complete synthesis of the β chains of
hemoglobin (Hb) (1). Most patients require regular blood transfusions and
chronic transfusions lead to pathologic iron accumulation. Iron overload is
usually the main cause of death, heart failure, skeletal complications such as
osteoporosis and osteopenia (2,3). Thalassemic patients are more prone to
bone mass loss, because of both the underlying disease and complications of
treatment. Anemia, overactive bone marrow, excess iron deposited in the
bones, deferoxamine (DFO) therapy and endocrine related problems are
the major mechanism of bone loss in β-thal major (β-TM) patients (4).
Previous studies suggested that osteopenia is one of the important factors of
mortality in young adults with β-thal (1). Osteopenia is characterized by
reduced bone mineral density (BMD) (2,5). The best way to measure BMD
is using dual energy X-ray absorptiometry (DXA), because of its high precision
and accuracy (5,6). Measurements are performed on the femur neck and
lumbar spine (6). In previous years, studies have proposed that genetic factors
play an important role in BMD regulation (2,5).
It has been found that genetic factors influence the BMD level in patients
with β-thal (6,7). Peroxisome proliferator-activated receptor-γ (PPARγ) is a
subtype of the PPAR family that regulate lipid and glucose metabolism (8).
Peroxisome proligerator-activated receptor-γ plays an important role in the
adipocytes differentiation, insulin sensitivity and also blood glucose control in
patient with type 2 diabetes (8). On the other hand, the PPARγ gene is located
on 3p25 in humans and is composed of nine exons (9,10). Several single
nucleotide polymorphisms (SNPs) have been detected in the PPARγ gene in
humans. One of these polymorphisms is Pro12Ala (rs1801282), which has the
substitution of proline to alanine at codon 12 in exon B (10). Recent studies
have suggested that PPARγ plays an important role in osteogenesis (11,12).
Based on this hypothesis that osteoblasts and adipocytes have a common
mesenchymal precursor, recent studies have shown that the activation of
PPARγ promoted adipocyte differentiation and simultaneously suppressed
their activity to differentiate into osteoblasts or stimulated their apoptosis
(13,14). The PPARγ activity appears to be important in regulating bone
metabolism through induction of osteoblast differentiation into osteoclasts
(11,15). Furthermore, studies have found that rs1801282 was significantly
associated with BMD of the lumbar spine in post-menopausal women (16).
In another study, in healthy Korean women, a significant association between
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this polymorphism and serum osteoprotegerin (OPG) level, a key inhibitor of
osteoclastogenesis, has been reported (17). However, no study has been
performed on the relationship between the Pro12Ala polymorphism and
BMD in β-TM patients. To test this hypothesis, we investigated the influence
of the Pro12Ala polymorphism PPARγ gene on variation of BMD in β-TM
patients.
MATERIALS AND METHODS
Subjects
In this cross-sectional study, the participants were 156 β-TM patients with
an age range of 20-45 years who were referred to the blood centers in Tehran
and Qazvin, between April 2009 andMay 2011. The study was approved by the
ethics committee of Qazvin University of Medical Sciences, Qazvin, Iran. The
age of onset of anemia and features of hemolysis on a peripheral smear
with increased fetal Hb was determined by a high performance liquid
chromatography (HPLC) technique, used for the diagnosis of β-thal. All the
patients were on oral calcium-vitamin D supplementation; patients without
any history of fracture were selected for this study.
Exclusion criteria included diabetes, endocrine disorders (thyroid, para-
thyroid and pituitary diseases) and retardation. Patients seropositive for Hbs
Ag, hepatitis C virus and human immunodeficiency virus were also excluded
from the study. Subjects who were receiving Biophosphonate at the time of
DXA were excluded. Serum ferritin estimation was done by an an enzyme-
linked immunosorbent assay (ELISA) kit (Alpco Diagnostics, Salem, NH,
USA).
Bone Mineral Density Measurements
BMD was measured in the femur neck and lumbar spine by DXA QDR
2000 (Hologic, Bedford, MA, USA).The coefficient of variability values of
DXAmeasurements was 1.0% for lumbar spine vertebra, and 1.2% for femoral
neck (5). Z-scores for the lumbar spine and femoral neck were calculated on
the basis of the standardized records of β-TM patients.
Genotyping
Genetic analyses were performed on genomic DNA that was isolated from
peripheral blood leukocytes by standard methods. A 295 bp sequence of the
PPARγ gene was amplified by polymerase chain reaction (PCR) in a DNA
thermal cycle (ABI PRISM™; Applied Biosystems, Foster City, CA, USA) using
oligonucleotide primers F: 5'-CTG ATG TCT TGA CTC ATG GG-3' and R: 5'-
GGA AGA CAA ACT ACA AGA GC-3'. The PCR condition were as follows: 15
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min. initial denaturation at 95˚C, and each PCR was subjected to 35 cycles at
94˚C for 30 seconds, 53˚C for 30 seconds, 72˚C for 30 seconds, followed by 7
min. at 72˚C (18). Restriction of the PCR product with the HgaI
enzyme generates fragments of 178/117 bp in rare homozygotes, 295/178/
117 bp in heterozygotes and 295 bp in common homozygotes (Figure 1).
Samples were electrophoresed on 3.0% agarose gel, and stained with ethi-
dium bromide.
Statistical Analyses
Values were presented as mean  SD (standard deviation), and statistical
significance was defined as p values less than 0.05. Statistically significant
differences in mean measurements between different PPARγ genotypes
were assessed by the t-test. Logistic regression analysis was performed to
evaluate associations between genotypes and osteopenia as a dependent vari-
able. All analyses were carried out using the Statistical Package for Social
Science (SPSS) for windows version 11.0 (Chicago, IL, USA).
RESULTS
The general characteristics of the study subjects, pre transfusion Hb,
serum ferritin, BMD Z-score and genotypes are presented in Table 1. The
mean age of the study population was 23.3  8.2 years, and the mean
FIGURE 1 Gel picture analysis with the restriction enzyme HgaI of the PPARγ Pro12Ala genotypes in
genomic DNAs of the study subjects. Lanes 1 and 8: molecular weight marker 50 bp; lanes 2 and 4:
homozygous GG; lanes 3 and 5: heterozygous CG: lanes 6 and 7: homozygous wild-type GG.
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bodymass index (BMI) was 20.4 3.3 kg/m2. The average Z-score of BMDwas
–2.11  1.07. The mean serum ferritin concentration was 1406 μg/L. All
patients were receiving chelation therapy with oral deferasirox (DFRA)
(26.4%) or subcutaneous DFO (73.6%). All patients were classified as having
normal BMDwith Z-score>-1 and as osteopenic with Z-score<-1 (Table 2). Of
the 156 subjects, 33 were normal and 123 had osteopenia. The frequency of
the PPARγ Pro12Ala CC genotype in normal subjects was significantly higher
(p¼ 0.024) than in patients with osteopenia (Table 3). Clinical and biochem-
ical characteristics of patients according to the Pro12Ala genotype are pre-
sented in Table 4. There were no significant differences in clinical and
biochemical characteristics between the two genotype groups. Furthermore,
a separate analysis of women and men also showed no significant differences
between clinical and biochemical characteristics (Table 5). The risk of
TABLE 1 Clinical and Biochemical Characteristics of Patients With β-Thalassemia Major
Age (years) 23.3  8.2
Women (%) 51.2
BMI (kg/m2) 20.4  3.3
Pro12Ala genotypes, n
●CC 121
●CG 35
Pre transfusion Hb (g/dL) 9.41  1.32
Serum ferritin (μg/L) (range 55.0–8900.0) 1406.0
BMD Z-score 2.11  1.07
Values are given as mean  SD, number or percentage with condition.
TABLE 2 Clinical and Biochemical Characteristics of Normal Patients Versus Osteopenia Patients
Normal(n ¼ 33) Osteopenic(n ¼ 123) p Value
Age (years) 33.90  8.2 31.80  8.1 0.19
Women (%) 47.00 52.00 0.64
BMI (kg/m2) 21.00  2.9 20.20  3.4 0.21
Pre transfusion Hb (g/dL) 9.53  1.38 9.38  1.32 0.56
Natural logarithm serum ferritin (mg/L) 6.62  1.08 6.80  1.01 0.39
Values are given as mean  SD. The patients were classified as having normal BMD if the Z-score was -1
and as osteopenic if the Z-score was <-1.
TABLE 3 Genotype Distributions in Normal Patients Versus Osteopenic Patients
Gene Normal (n ¼ 33) Osteopenic (n ¼ 123) p Value
Pro12Ala genotypes, n
●CC 21 100 0.024
●CG 12 23
568 M. Sahmani et al.
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osteopenia in different genetic groups was estimated by logistic regression
analysis (Table 6). This analysis showed that the risk of osteopenia in subjects
with a homozygous CC genotype was significantly higher [odds ratio (OR) ¼
2.59; p ¼ 0.03]. When the men and women were analyzed separately, the
association between the PPARγ genotype and osteopenia were no longer
TABLE 4 Clinical and Biochemical Characteristics According to Pro12Ala Genotypes
CC CG p Value
n 121 35
Age (years) 32.20  7.9 32.70  9.9 0.79
BMI (kg/m2) 20.50  3.5 20.20  3.0 0.69
Pre transfusion Hb (g/dL) 9.38  1.38 9.50  1.14 0.66
Natural logarithm serum ferritin (mg/L) 6.81  0.98 6.63  1.19 0.37
Values are given as mean  SD.
TABLE 5 Clinical and Biochemical Characteristics in Men and Women According to the Pro12Ala
Genotypes
Men CC CG p Value
n 56 21
Age (years) 32.60  8.3 32.30  10.4 0.89
BMI (kg/m2) 19.50  3.1 20.00  2.1 0.51
Pre transfusion Hb (g/dL) 9.57  1.46 9.60  1.27 0.93
Natural logarithm serum ferritin (mg/L) 6.84  0.92 6.76  1.16 0.76
Women CC CG p Value
n 65 14
Age (years) 31.90  7.7 33.10  9.4 0.59
BMI (kg/m2) 21.30  3.5 20.50  4.1 0.47
Pre transfusion Hb (g/dL) 9.22  1.30 9.34  0.94 0.75
Natural logarithm serum ferritin (mg/L) 6.78  1.04 6.43  1.23 0.28
Values are given as mean  SD.
TABLE 6 Logistic Regression Analyses of the Pro12Ala Genotypes With Respect to the Presence of
Osteopenia as a Dependent Variablea
95% CI OR p Value
All patients 1.11–6.05 2.59 0.03
Men 1.03–9.98 3.21 0.04
Women 0.52–7.45 1.96 0.32
Values are given as 95% confidence interval (95% CI), the odds ratio (OR) and p value level of
significance, which shows the association between genotypes and low BMD Z-scores. The patients were
classified as having normal BMD if the Z-score was -1 and as osteopenic if the Z-score was <-1.
aAdjusted for age and BMI.
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significant in women (OR¼ 1.96; p¼ 0.32), while the association in men (OR
¼ 3.21; p ¼ 0.04) remained significant.
DISCUSSION
β-Thalassemia is a disease resulting from genetic defects caused by
impaired synthesis of Hb β chains (1). Bone loss is one of the major complica-
tions of this disease. Various factors such as genetic, environmental, nutri-
tional and hormonal factors play roles in the incidence of osteopenia in β-TM
patients (19). Consistent with previous studies (6), our study showed a high
prevalence, about 80.0%, of osteopenia in β-TM patients. Study of genetic
polymorphisms associated with susceptibility to osteopenia in thalassemia
patients can give us better insight into the role of genetic factors in this
disease. In this study, we showed that the Pro12Ala polymorphism of the
PPARγ gene may play an important role in the pathogenesis of thalassemic
osteopenia. Our finding also showed that compared with the common homo-
zygous genotype (CC), the risk of osteopenia is lower in the heterozygous
genotype (CG). A previous study suggested that there is a significant negative
correlation between age and BMD in patients with thalassemia (20). However,
such a relationship was not observed in our study. Some reports showed that
there were no significant differences in Z-score level betweenmen and women
(21), while other studies have shown that the Z-scores are higher in men than
in women (22). Our data showed no statistically significant independent
association between the PPARγ Pro12Ala genotype and BMD levels in
women, whereas in men the risk of osteopenia was lower for those with the
Pro12Ala polymorphism. Since women in this study were not menopausal, it
was suggested that (probably) female sex hormones, especially estrogens, can
be an important factor in preventing bone loss, and consequently reduce
osteopenia in women.
The PPARγ gene was first identified in white adipose tissue. Essentially, it
has an important role in the final stages of differentiation of pre adipocyte into
mature adipocytes (5,23). The hypothesis that PPARγmay also be involved in
bone metabolism has arisen from the fact that osteoblasts and adipocytes are
grown from common mesenchymal precursor cells (23), although this con-
clusion still needs further research before it is accepted (24). There are
several studies that have shown the role of PPARγ in differentiation and
activation osteoblasts (12,13). Using heterozygous mice that had disrupted
the PPARγ gene (PPARþ/–) and a 50.0% reduction in PPARγ gene expres-
sion, it has been shown that insufficiency in PPARγ activity increases bone
mass via stimulation of osteoblastogenesis from bone marrow precursors
(25,26). These studies have shown the negative role of PPARγ gene activation
on bone formation (25). Accordingly, Mbalaviele et al. (15) suggested that the
570 M. Sahmani et al.
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activity of the PPARγ pathway by an endogenic ligand, would prevent the
effects of OPG ligand, a key inhibitor of osteoclastogenesis. It was probably
due to inhibition of receptor-activated nuclear factor-kappa B (NF-κB) and
receptor activator of nuclear factor-kappa B ligand (RANKL), blocking the
NF-κB pathway, which is essential for osteoclastic precursors (27). The Chan
et al. (11) study showed that the addition of a PPARγ agonist in cultured
human peripheral blood mononuclear cells prevents formation of multinu-
cleated osteoclasts. Okazaki et al. (28) had also suggested that the reduction of
the number of osteoclast cells following treatment with thiazolidinedione
(PPARγ agonists) are enhanced by parathyroid hormone (PTH) and 25-
hydroxy vitamin D (25-OHD), suggesting the inhibitory effect of PPARγ
gene activation on bone resorption. In our study, patients with the Pro2Ala
CG genotype had higher Z-score values. Conversely, it has been shown that the
BMD values were not significantly different between the genotype groups
(17). Furthermore, Masud and Ye (29) showed that subjects with the
Pro12Ala genotype had significantly higher BMI or obesity than those without
the alanine allele (29). In our study, this relationship was not significant. On
the other hand, our findings showed that the effect of the Pro12Ala poly-
morphism on BMD in β-thal patients is independent of BMI. These contra-
dictions seem to be due to racial differences in the alanine allele frequency
and distribution of BMI. Our study limitations include unmeasured confound-
ing factors such as dietary fat, 25-OHD and OPG (3).
In conclusion, the present study suggested novel evidence of significant
beneficial effects of the PPARγ Pro12Ala polymorphism on BMD level, and
consequently, osteopenia in β-thal patients. This relationship showed that
study of potential genetic effects can offer important insight to improve the
management strategy of β-TM patients at high risk for osteopenia.
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